Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The mixture of selinexor plus ruxolitinib met the primary co-primary endpoint demonstrating a statistically vital enchancment of spleen quantity discount ...
